Yutaka Matsui1,2, Takashi Maruyama1,3, Masayuki Nitta1,3, Taiichi Saito3, Shunsuke Tsuzuki3, Manabu Tamura1,3, Kaori Kusuda1, Yasukazu Fukuya1, Hidetsugu Asano1,2, Takakazu Kawamata3, Ken Masamune1, Yoshihiro Muragaki4,5. 1. Faculty of Advanced Techno-Surgery, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. 2. Technical Department, Atom Medical Corporation, Tokyo, Japan. 3. Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan. 4. Faculty of Advanced Techno-Surgery, Institute of Advanced Biomedical Engineering and Science, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan. ymuragaki@twmu.ac.jp. 5. Department of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan. ymuragaki@twmu.ac.jp.
Abstract
INTRODUCTION: It is useful to know the molecular subtype of lower-grade gliomas (LGG) when deciding on a treatment strategy. This study aims to diagnose this preoperatively. METHODS: A deep learning model was developed to predict the 3-group molecular subtype using multimodal data including magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT). The performance was evaluated using leave-one-out cross validation with a dataset containing information from 217 LGG patients. RESULTS: The model performed best when the dataset contained MRI, PET, and CT data. The model could predict the molecular subtype with an accuracy of 96.6% for the training dataset and 68.7% for the test dataset. The model achieved test accuracies of 58.5%, 60.4%, and 59.4% when the dataset contained only MRI, MRI and PET, and MRI and CT data, respectively. The conventional method used to predict mutations in the isocitrate dehydrogenase (IDH) gene and the codeletion of chromosome arms 1p and 19q (1p/19q) sequentially had an overall accuracy of 65.9%. This is 2.8 percent point lower than the proposed method, which predicts the 3-group molecular subtype directly. CONCLUSIONS: A deep learning model was developed to diagnose the molecular subtype preoperatively based on multi-modality data in order to predict the 3-group classification directly. Cross-validation showed that the proposed model had an overall accuracy of 68.7% for the test dataset. This is the first model to double the expected value for a 3-group classification problem, when predicting the LGG molecular subtype.
INTRODUCTION: It is useful to know the molecular subtype of lower-grade gliomas (LGG) when deciding on a treatment strategy. This study aims to diagnose this preoperatively. METHODS: A deep learning model was developed to predict the 3-group molecular subtype using multimodal data including magnetic resonance imaging (MRI), positron emission tomography (PET), and computed tomography (CT). The performance was evaluated using leave-one-out cross validation with a dataset containing information from 217 LGG patients. RESULTS: The model performed best when the dataset contained MRI, PET, and CT data. The model could predict the molecular subtype with an accuracy of 96.6% for the training dataset and 68.7% for the test dataset. The model achieved test accuracies of 58.5%, 60.4%, and 59.4% when the dataset contained only MRI, MRI and PET, and MRI and CT data, respectively. The conventional method used to predict mutations in the isocitrate dehydrogenase (IDH) gene and the codeletion of chromosome arms 1p and 19q (1p/19q) sequentially had an overall accuracy of 65.9%. This is 2.8 percent point lower than the proposed method, which predicts the 3-group molecular subtype directly. CONCLUSIONS: A deep learning model was developed to diagnose the molecular subtype preoperatively based on multi-modality data in order to predict the 3-group classification directly. Cross-validation showed that the proposed model had an overall accuracy of 68.7% for the test dataset. This is the first model to double the expected value for a 3-group classification problem, when predicting the LGG molecular subtype.
Authors: Sohil H Patel; Laila M Poisson; Daniel J Brat; Yueren Zhou; Lee Cooper; Matija Snuderl; Cheddhi Thomas; Ana M Franceschi; Brent Griffith; Adam E Flanders; John G Golfinos; Andrew S Chi; Rajan Jain Journal: Clin Cancer Res Date: 2017-07-27 Impact factor: 12.531
Authors: Ben Shofty; Moran Artzi; Dafna Ben Bashat; Gilad Liberman; Oz Haim; Alon Kashanian; Felix Bokstein; Deborah T Blumenthal; Zvi Ram; Tal Shahar Journal: Int J Comput Assist Radiol Surg Date: 2017-12-21 Impact factor: 2.924
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: E Aliotta; H Nourzadeh; P P Batchala; D Schiff; M B Lopes; J T Druzgal; S Mukherjee; S H Patel Journal: AJNR Am J Neuroradiol Date: 2019-08-14 Impact factor: 3.825
Authors: Martinus P G Broen; Marion Smits; Maarten M J Wijnenga; Hendrikus J Dubbink; Monique H M E Anten; Olaf E M G Schijns; Jan Beckervordersandforth; Alida A Postma; Martin J van den Bent Journal: Neuro Oncol Date: 2018-09-03 Impact factor: 13.029
Authors: Arian Lasocki; Michael E Buckland; Katharine J Drummond; Heng Wei; Jing Xie; Michael Christie; Andrew Neal; Frank Gaillard Journal: Neuroradiology Date: 2022-05-24 Impact factor: 2.804
Authors: Chandan Ganesh Bangalore Yogananda; Bhavya R Shah; Frank F Yu; Marco C Pinho; Sahil S Nalawade; Gowtham K Murugesan; Benjamin C Wagner; Bruce Mickey; Toral R Patel; Baowei Fei; Ananth J Madhuranthakam; Joseph A Maldjian Journal: Neurooncol Adv Date: 2020-07-17
Authors: Marcus Unterrainer; Viktoria Ruf; Katharina von Rohr; Bogdana Suchorska; Lena Maria Mittlmeier; Leonie Beyer; Matthias Brendel; Vera Wenter; Wolfgang G Kunz; Peter Bartenstein; Jochen Herms; Maximilian Niyazi; Jörg C Tonn; Nathalie Lisa Albert Journal: Front Oncol Date: 2021-04-27 Impact factor: 6.244
Authors: Evi J van Kempen; Max Post; Manoj Mannil; Benno Kusters; Mark Ter Laan; Frederick J A Meijer; Dylan J H A Henssen Journal: Cancers (Basel) Date: 2021-05-26 Impact factor: 6.639
Authors: Nicholas Nuechterlein; Beibin Li; Abdullah Feroze; Eric C Holland; Linda Shapiro; David Haynor; James Fink; Patrick J Cimino Journal: Neurooncol Adv Date: 2021-02-15